Pfizer Begins Trial Of mRNA Flu Vaccine

Reuters (9/27, Mishra) reports that on Monday, Pfizer announced “it had dosed the first patient in a trial testing a flu vaccine based on messenger RNA” that “will test the vaccine in healthy adults ages 65- 85.”